Abstract
The field of viral hepatitis including that of hepatitis B is rapidly evolving. There continues to be an explosion of new information not only on treatment options but also on management of those with acute and/or chronic hepatitis B. In light of this, the focus of this chapter is not on addressing information typically in textbooks of hepatology but rather on a framework of specific patient management questions which may be faced by the provider in the care of the patient affected by hepatitis B infection.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lada O, Benhamou Y, Poynard T, Thibault V. Coexistance of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J Virol. 2006;80(6):2968–75.
Galati G, Vincentis A, Vespasiani-Gentilucci U, Gallo P, Vincenti D, Solmone M, et al. Coexistance of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterol. 2014;14(94):1–4.
Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, et al. Clinical and virological significance of the co-existance of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology. 2007;367:30–40.
Hoofnagle J, Doo E, Liang J, Fleischer R, Lok A. Management of hepatitis B; summary of clinical research workshop. Hepatology. 2007;45(4):1056–75.
Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y. American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppresive drug therapy. Gastroenterology. 2015;148(1):215–9.
Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–30.
LeFevre M. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventative Services Task Force Recommendation Statement. Ann Intern Med. 2014;161(1):58–67.
Maruyama T, Schodel F, Iino S, Koike K, Yasuda K, Peterson D, et al. Distinguishing between acute and symptomatic chronic hepatitis B virus infection. Hepatology. 1988;8(4):766–70.
Draelos M, Morgan T, Schifman R, Sampliner R. Significance of isolated antibody to hepatits B core antigen determined by immune response to hepatitis B vaccination. JAMA. 1987;258(9):1193–5.
Al-Mekhaizeem K, Miriello M, Sherker A. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. Can Med Assoc J. 2001;165(8):1063–4.
Lok A, McMahon J. AASLD practice guidelines: chronic hepatitis B. Hepatology. 2007;45(2):507–39.
Al-Mahtab M, Rahman S, Akbar S, Kamal M, Khan M. Clinical use of liver biopsy for the diagnosis and management of inactive and aymptomatic hepatitis B virus carriers in Bangladesh. J Med Virol. 2010;82:1350–4.
Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.
Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR. 2006;54(RR16):1–23.
Sarkar M, Terrault N. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology. 2014;60(2):448–51.
Reddy K, Pavri T. Long-term safety of HBV therapies and when to stop therapy. Crit Issues HBV. 2014;1(1):17–9.
Sorrell M, Belongia E, Costa J, Gareen I, Grem J, Inadomi J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104–10.
Chu C, Liaw Y. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26(2):142–52.
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.
Keefe E, Dieterich D, Han S, Jacobson I, Martin P, Schiff E, et al. A treatment algoright for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2(2):87–106.
Wong R, Gish R. Implementing best practices when initiating hepatitis B virus therapy. Crit Issues HBV. 2014;1(1):5–10.
Lau D, Javaid A. Evaluating underlying causes of HBV treatment failure. Crit Issues HBV. 2014;1(1):13–5.
Lok A, McMajon B. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.
Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53(3):449.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Taranukha, T., Kounev, V. (2017). Viral Hepatitis: Hepatitis B (& D). In: Saeian, K., Shaker, R. (eds) Liver Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-30103-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-30103-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30101-3
Online ISBN: 978-3-319-30103-7
eBook Packages: MedicineMedicine (R0)